BRPI0821461A8 - Uso de canabinóides em combinação com um medicamento antipsicótico - Google Patents

Uso de canabinóides em combinação com um medicamento antipsicótico

Info

Publication number
BRPI0821461A8
BRPI0821461A8 BRPI0821461A BRPI0821461A BRPI0821461A8 BR PI0821461 A8 BRPI0821461 A8 BR PI0821461A8 BR PI0821461 A BRPI0821461 A BR PI0821461A BR PI0821461 A BRPI0821461 A BR PI0821461A BR PI0821461 A8 BRPI0821461 A8 BR PI0821461A8
Authority
BR
Brazil
Prior art keywords
cannabinoids
combination
antipsychotic
acid
antipsychotic drug
Prior art date
Application number
BRPI0821461A
Other languages
English (en)
Inventor
Kikuchi Tetsuro
Maeda Kenji
Robson Philip
Stott Colin
Guy Geoffrey
Original Assignee
Otsuka Pharma Co Ltd
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39144704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821461(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd, Gw Pharma Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0821461A2 publication Critical patent/BRPI0821461A2/pt
Publication of BRPI0821461A8 publication Critical patent/BRPI0821461A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

USO DE CANABINÓIDES EM COMBINAÇÃO COM UM MEDICAMENTO ANTIPSICÓTICO A presente invenção está relacionada ao uso de um ou mais canabinóides em combinação com um ou mais medicamentos antipsicóticos para uso na prevenção ou tratamento de psicose e distúrbios psicóticos. De preferência, os (um ou mais) canabinóides são escolhidos do grupo: canabidiol (CBD); ácido canabidiólico (CBDA); tetrahidrocanabivarin (THCV); ácido canabidiólico (CBDA); tetrahidrocanabivarin (THCVA); canabicromeno (CBC); ácido canabicromênico (CBCA); canabigerol (CBG) e ácido canabigerólico (CBGA). De preferência, a medicação antipsicótica é uma medicação antipsicótica atípica.
BRPI0821461A 2008-01-04 2008-12-17 Uso de canabinóides em combinação com um medicamento antipsicótico BRPI0821461A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0800390A GB2456183A (en) 2008-01-04 2008-01-04 Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
PCT/GB2008/004217 WO2009087351A1 (en) 2008-01-04 2008-12-17 Use of cannabinoids in combination with an anti-psychotic medicament

Publications (2)

Publication Number Publication Date
BRPI0821461A2 BRPI0821461A2 (pt) 2015-06-16
BRPI0821461A8 true BRPI0821461A8 (pt) 2018-04-03

Family

ID=39144704

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821461A BRPI0821461A8 (pt) 2008-01-04 2008-12-17 Uso de canabinóides em combinação com um medicamento antipsicótico

Country Status (25)

Country Link
US (1) US9017737B2 (pt)
EP (3) EP2249848B1 (pt)
JP (1) JP5409650B2 (pt)
KR (1) KR101631518B1 (pt)
CN (1) CN101939017B (pt)
AR (1) AR070063A1 (pt)
AU (1) AU2008346285B2 (pt)
BR (1) BRPI0821461A8 (pt)
CA (1) CA2708921C (pt)
CL (1) CL2008003902A1 (pt)
CO (1) CO6290695A2 (pt)
ES (3) ES2574155T3 (pt)
GB (3) GB2456183A (pt)
HU (2) HUE046780T2 (pt)
IL (1) IL206784A0 (pt)
MX (1) MX2010007073A (pt)
NZ (1) NZ586648A (pt)
PE (2) PE20141249A1 (pt)
PL (2) PL2609928T3 (pt)
PT (2) PT2609928T (pt)
RU (1) RU2503448C2 (pt)
TW (2) TWI519299B (pt)
UA (1) UA103472C2 (pt)
WO (1) WO2009087351A1 (pt)
ZA (1) ZA201005443B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
WO2011117429A1 (es) * 2010-03-26 2011-09-29 Vivacell Biotechnology España, S.L Derivados quinona de cannabinoides
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
IL298116A (en) 2010-12-22 2023-01-01 Syqe Medical Ltd Method and system for drug delivery
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
AU2014302410B2 (en) 2013-06-26 2019-06-13 Amgen Inc. CB1 receptor antigen-binding proteins and uses thereof
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
CN105873566B (zh) 2013-10-29 2019-06-07 艾克制药有限公司 含有δ9-四氢大麻酚的压制片剂、其制造方法及此类片剂在口服治疗中的用途
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
RU2690401C2 (ru) 2014-06-30 2019-06-03 Сике Медикал Лтд. Способ и устройство для испарения и ингаляции выделенных веществ
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
JP6747988B2 (ja) * 2014-06-30 2020-08-26 サイケ メディカル リミテッドＳｙｑｅ Ｍｅｄｉｃａｌ Ｌｔｄ． 活性薬剤肺送達のための方法、装置及びシステム
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
PL3160552T3 (pl) 2014-06-30 2020-03-31 Syqe Medical Ltd. Wkład z dawką leku dla urządzenia inhalacyjnego
KR102482733B1 (ko) 2014-06-30 2022-12-29 사이키 메디컬 엘티디. 유동 조절 흡입기 디바이스
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9539295B2 (en) 2014-12-05 2017-01-10 Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP3851102B1 (en) 2016-01-06 2025-04-16 Syqe Medical Ltd. Low dose therapeutic treatment
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
AU2017315273B2 (en) * 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CN108078984B (zh) * 2016-11-23 2020-11-20 汉义生物科技（北京）有限公司 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
CN108143726B (zh) * 2016-12-02 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US12414936B2 (en) 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019099745A1 (en) * 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3755318B1 (en) * 2018-02-20 2022-08-24 MyMD Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2020188569A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022103638A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
IL136839A (en) * 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
SK287592B6 (sk) * 2001-03-22 2011-03-04 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
US20050154202A1 (en) * 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
ES2471190T3 (es) * 2003-06-24 2014-06-25 Gw Pharma Limited Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
CA2538291A1 (en) * 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
RU2006126122A (ru) * 2003-12-19 2008-01-27 Бристол-Маерс Сквибб Компани (Us) Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
JP2009537523A (ja) * 2006-05-15 2009-10-29 メルク エンド カムパニー インコーポレーテッド 三級アルコールのプロドラッグ
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
DE602006017669D1 (de) 2006-06-12 2010-12-02 Camp Scandinavia Ab Rahmen für eine Hyperextensionsorthese
US8481085B2 (en) * 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US8889076B2 (en) * 2008-12-29 2014-11-18 Uop Llc Fluid catalytic cracking system and process

Also Published As

Publication number Publication date
EP2609928A2 (en) 2013-07-03
ZA201005443B (en) 2011-04-28
EP2609928B1 (en) 2019-07-17
CO6290695A2 (es) 2011-06-20
US20110038958A1 (en) 2011-02-17
GB0800390D0 (en) 2008-02-20
HUE047214T2 (hu) 2020-04-28
ES2750728T3 (es) 2020-03-26
GB201216932D0 (en) 2012-11-07
TWI519299B (zh) 2016-02-01
US9017737B2 (en) 2015-04-28
CA2708921C (en) 2018-03-20
IL206784A0 (en) 2010-12-30
EP3095452A1 (en) 2016-11-23
PL2609928T3 (pl) 2020-06-01
EP2249848A1 (en) 2010-11-17
GB2456183A (en) 2009-07-08
AU2008346285A1 (en) 2009-07-16
TW201436791A (zh) 2014-10-01
PE20091361A1 (es) 2009-09-23
AR070063A1 (es) 2010-03-10
CA2708921A1 (en) 2009-07-16
ES2751117T3 (es) 2020-03-30
JP2011508765A (ja) 2011-03-17
NZ586648A (en) 2012-12-21
UA103472C2 (uk) 2013-10-25
ES2574155T3 (es) 2016-06-15
CN101939017A (zh) 2011-01-05
EP3095452B1 (en) 2019-07-17
RU2010132649A (ru) 2012-02-10
GB2468828A (en) 2010-09-22
EP2249848B1 (en) 2016-05-18
JP5409650B2 (ja) 2014-02-05
MX2010007073A (es) 2010-12-02
CN101939017B (zh) 2016-08-17
TW200936127A (en) 2009-09-01
RU2503448C2 (ru) 2014-01-10
GB2468828B (en) 2012-11-07
GB201012953D0 (en) 2010-09-15
AU2008346285B2 (en) 2015-04-02
CL2008003902A1 (es) 2009-07-24
WO2009087351A1 (en) 2009-07-16
BRPI0821461A2 (pt) 2015-06-16
PT2609928T (pt) 2019-10-29
HUE046780T2 (hu) 2020-03-30
PT3095452T (pt) 2019-10-30
PL3095452T3 (pl) 2020-05-18
KR101631518B1 (ko) 2016-06-24
PE20141249A1 (es) 2014-10-03
EP2609928A3 (en) 2013-12-18
KR20100113099A (ko) 2010-10-20

Similar Documents

Publication Publication Date Title
BRPI0821461A8 (pt) Uso de canabinóides em combinação com um medicamento antipsicótico
BR112014007519A2 (pt) composição farmacêutica compreendendo os fitocanabinóides canabidivarina (cbdv) e o canabidiol (cbd)
PH12013502148A1 (en) Cannabinoids for use in the treatment of neuropathic pain
CO2020009747A2 (es) Métodos para purificar cannabinoides usando cromatografía líquido-líquido
Jia et al. Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor‐mediated type 2 NADPH oxidase
BRPI0911384A8 (pt) Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm)
BR112012024480A8 (pt) Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsia
GB201111261D0 (en) Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
US10596159B2 (en) Method and composition for treating cachexia and eating disorders
MX364633B (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.
IL291864A (en) Combinations of cannabinoids and acyl-ethanol-amines
Zhou et al. Morusin inhibits the growth of human colorectal cancer HCT116-derived sphere-forming cells via the inactivation of Akt pathway
Mo et al. Morin has protective potential against ER stress induced apoptosis in renal proximal tubular HK-2 cells
GB201120067D0 (en) Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
GB2564459A8 (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
BR112022021640A2 (pt) Usos e formulações de canabinoides
EP4161900A4 (en) Cannabidiolic acid (cbda) derivatives and uses thereof
WO2022167822A3 (en) A cannabinoid mixture
Feng et al. (−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway
Di Majo et al. Flavonols and flavan-3-ols as modulators of xanthine oxidase and manganese superoxide dismutase activity
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
Deslauriers et al. Antipsychotic‐induced DRD2 upregulation and its prevention by α‐lipoic acid in SH‐SY5Y Neuroblastoma cells
TH144555A (th) การใช้แคนนาบินอยด์ร่วมกับยาต้านโรคจิต
Jiang et al. Baicalein ameliorates lipid accumulation in HepG2 cells via the pregnane X receptor signaling pathway

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO. LTD (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO.

B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B11R Patent application dismissed according to article 229 of the patent law [chapter 11.18 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021.